When you choose to publish with PLOS, your research makes an impact. Make your work accessible to all, without restrictions, and accelerate scientific discovery with options like preprints and published peer review that make your work more Open.

Journals
More Content
PLOS BLOGS EveryONE
Browse all PLOS Blogs
Browse all PLOS Blogs

A Perfect Match: A Multidisciplinary Conference for the Ultimate Multidisciplinary Journal

Rachel Bernstein Aggregators

Despite the ongoing situation in Boston, at this point the Experimental Biology 2013 conference is scheduled to begin this Sunday, and PLOS ONE is looking forward to being there to meet our authors, editors, reviewers, and anyone interested in joining the PLOS ONE community.

We’ll be at booth #547 in the Exhibitor’s Hall, Sunday through Tuesday, 9 am to 4 pm. We will also be hosting an informal meeting at the booth for editors and those interested in joining our editorial board on Monday, April 22, from 12 to 1:30. We hope to see you there!

The conference is an exciting multidisciplinary event, with a variety of participating societies that cover a wide range of biological topics, including the American Society for Biochemistry and Molecular Biology (ASBMB), American Society for Pharmacology and Experimental Therapeutics (ASPET), and the American Physiological Society (APS).

The diversity and breadth of the topics covered at the conference is a perfect match for PLOS ONE. As a multidisciplinary journal, we publish work in all the represented fields, and we are also a great venue for the interdisciplinary work this conference aims to promote. While discipline-specific journals can create artificial barriers between “traditional” research areas, PLOS ONE’s coverage of all fields of science and medicine fosters interdisciplinary research and productive collaboration between fields that might have previously been separated.

We hope to see you at booth #547. For the latest updates on the conference, please visit the conference homepage and follow @ExpBio and #EB2013 on Twitter.

Back to top